SlideShare a Scribd company logo
Uterine Sarcoma
And Its
Management
G . Lakshmi Deepthi
Sarcoma : ( sarx -"flesh")
is a cancer that arises from transformed cells
of mesenchymal origin
Uterine sarcomas arise from dividing cell
populations in the myometrium or connective
tissue elements within the endometrium
Uterine sarcomas :
1% of female genital tract cancers
3-7% of uterine cancers
WHO classification
2014
WHO classification 2014
Uterine Sarcoma Classification :
NCCN 2016
• Low grade endometrial stromal sarcoma(ESS)
• High grade ESS
• Undifferentiated Uterine Sarcoma(UUS)
• Uterine Leiomyosarcoma (uLMS)
Other Rare Uterine Mesenchymal Sarcoma Subtypes :
• Adenosarcoma
• PEComas
• Rhabdomyosarcoma
General Features :
 Each group of tumors is distinct with respect to pattern of
spread, pathologic features, prognostic factors and response to
treatment.
 Incidence : carcinosarcomas (45%) > leiomyosarcomas,
(40%) > endometrial stromal sarcomas(15%)
 Age-related incidences vary among the histologic types. The
mean age at diagnosis for endometrial stromal sarcoma is 41
years, for leiomyosarcoma 53.5 years, for adenosarcoma
57.4 years, and for carcinosarcoma 65 years
 Staging system different for each
Leiomyosarcoma and ESS
Adenosarcoma
Carcinosarcoma
Rare sarcomas
 Clinical features
 Pathology
 Diagnostic workup
 Treatment
• Leiomyosarcoma
• ESS
• Carcinosarcoma
Leiomyosarcoma
malignant neoplasm composed of cells demonstrating smooth muscle
differentiation true sarcomas
 1-2% of all uterine tumors
 30% of all uterine sarcomas
 >40yrs of age
 Presentation :
vaginal bleeding (56%)
pelvic mass(54%)
pelvic pain (22%)
Diagnosis:
 Preoperative– endometrial sampling
pelvic ultrasound
MRI
CT chest
 Postoperative –
---No second surgical procedure for the sole purpose of
staging.
---postop CT of the chest, abdomen, and pelvis.
 Pelvic ultrasound is typically the first-line study
 S/o sarcoma --mixed echogenic and poor echogenic
parts; central necrosis
 Color Doppler -- irregular vessel distribution, low
impedance to flow, and high peak systolic velocity
 CT does not reliably differentiate between leiomyomas
and uterine sarcomas
T1 MR T2 MR
• MRI vary and include a lobulated mass of high-signal intensity on T2-
weighted images,
• scattered foci of haemorrhages or necrosis
• These necrotic areas are -- slightly higher intensity on T1-weighted
images and as heterogeneous areas on T2-weighted images.
• A consistent finding -- the absence of calcifications.
Pathology :
Gross:
 solitary intramural masses
 Average 8cm in diameter
 fleshy with poorly defined margins.
 Cut section : typically soft, bulging, fleshy, necrotic,
hemorrhagic, and lacks the prominent whorled
appearance of leiomyomas.
Microscopic :Stanford criteria
High nuclear atypia
Coagulative necrosis
High mitotic rate
Variants :
Epitheloid :
Necrosis absent
Mild nuclear atypia
Less mitotic rate
Myxoid :
hypo cellular
Mild nuclear atypia
IHC :
 Positive for smooth muscle markers
Desmin ,H-Caldeson , actin, histone deacetylase 8
 Epitheloid and myxoid variants are less immunoreactive
 Epitheloid –keratin ,EMA positive
 ER+,PR +,androgen receptor + --30-40 % of cases
 Ki 67 increased
 P16 overexpressed – differentiate between benign and
malignant
Staging :FIGO 2009
Total abdominal Hysterectomy
+/-
B/L Salpingo-oopherectomy
TREATMENT
Disease confined to uterus Disease extending outside uterus
TAH with BSO and surgical
cytoreduction of intra-
abdominal and
retroperitoneal disease
Lymphadenectomy
???
 If the pelvic nodes are palpably enlarged intraoperatively
 there is evidence of extrauterine disease
LN involvement <5%
1992
Prognostic factors :
 Tumor size (>10cm)
 Mitotic rate (20 MF/10HPF)
 Ki 67 (>10%)
 Bcl 2 (Negative)
Overall prognosis :
 Poor even in stage I disease
 Recurrence – 53-71% ---lungs -40%
Pelvis – 13%
 5yr survival – 15-25% of cases
 Median survival – 10 months
STAGE 5YR OS
I 76%
II 60%
III 45%
IV 29%
Adjuvant Treatment :
 Chemotherapy or Pelvic radiation can be considered
following surgery for leiomyosarcoma (LMS).
 However, whether any form of adjuvant therapy
improves survival compared with observation is not
known.
 Early stage disease (I or II)– it is not clear if any
intervention improves the survival outcomes compared
with post-surgical surveillance.
Observation is preferred
Neither PFS, nor OS nor pelvic control was
improved by radiotherapy. Therefore, radiation
therapy is not indicated in patients with stage I or
II LMS after complete resection
Stage I or II sarcomas, varied histology
• women treated with doxorubicin had a lower
recurrence rate compared with those not treated
with chemotherapy (41 versus 53 percent), this was
not statistically significant.
• In addition, adjuvant doxorubicin had no impact on
progression-free or overall survival.
• To estimate 2yr and 3yr PFS….n=46
• 4 cycles of gemcitabine plus docetaxel f/b 4 cycles of
doxorubicin
• 2yr PFS – 78% 3yr PFS – 57%
• median time to recurrence was 27 month
N=27
Single arm,phase II
Completely resected I-IV2yr PFS-59% Median PFS -39months
Advanced stage – Radiotherapy??
• Sampath et al.--significantly reduced local
failure rate at 5 years of 2%, compared with
16% in the surgery-alone group
NCCN– 2B Recommendation in LMS
 high rates of initial metastatic failure in LMS
 adjuvant pelvic radiotherapy does not appear to have a
survival benefit in LMS,
 although it may reduce local pelvic recurrences, possibly
for disease that has spread beyond the uterus (FIGO
stages II–IV)
so might be considered for these higher risk
women in order to improve local disease control.
Chemotherapy In Uterine
Leiomyosarcomas :
GOG 277
 chemotherapy with doxorubicin or
docetaxel/gemcitabine is now used for advanced or
recurrent disease, with response rates ranging from
27% to 36%
• Early-stage --leiomyosarcoma,
carcinosarcoma, and
endometrial stromal sarcoma
• CRT arm--increased 3-year DFS
(55% vs 41%; P=0.048),
• But no improvement in 3-year
OS
Combined Modality
Metastatic or inoperable disease
:
 Palliative intent.
 Chemotherapy --good performance status and in
whom organ function permits the use of
cytotoxic chemotherapy.
 For other patients--palliative care
 Doxorubicin-based treatment first-line choice.
 Gemcitabine plus docetaxel--first- or second-
line therapy
Alternatives Or Second Line Therapy:
 Doxorubicin based
 Gemcitabine alone RR-20%
 Ifosfamide alone – RR-17%
 Ifosfamide + Doxorubicin – RR 30%
 Trabectedin –progression on anthracyclines –ORR-
16%
 Pazopanib
 Erbulin
 Endocrine Therapy– ORR<10%--Aromatase
inhibitors can be considered for ER/PR- expressing
uLMS
Follow Up:
 Physical exam every three to four months and
chest, abdomen, and pelvic imaging every three
to four months for two to three years,
 every 6 to 12 months for the next two years.
Recurrence
STUMP :Smooth Muscle Tumors Of
Uncertain Malignant Potential
 Have high malignancy features but not falling into
diagnostic criteria for leiomyosarcoma .
 Microscopic : tumor cell necrosis
necrosis of uncertain type >10 MF/10HPF
diffuse atypia
borderline mitotic counts
 Favorable prognosis
 Treatment – only follow up after total hysterectomy
Endometrial Stromal Sarcoma
• 0.2–1% of all uterine malignancies
• 6–20% of all uterine sarcomas
Norris and Taylor 1965 (old
terminology)
 Endometrial Stromal Nodule
 Endometrial Stromal Sarcoma
– Low grade (< 10 mits/10 hpf)
High grade (>10 mits/10 hpf)
 Undifferentiated Uterine Sarcoma
Mitotic rate does not predict recurrence
WHO Classification 2004
WHO 2004
 Endometrial Stromal Nodule
 Endometrial Stromal Sarcoma (“low grade”)
 Undifferentiated Uterine Sarcoma
WHO 2014
 Endometrial stromal nodule (ESN)
 Low grade ESS
 High grade ESS
 Undifferentiated
Cytogenetics
 2nd most common mesenchymal uterine
tumors (<10%)
 ESN and low grade ESS are similar in
morphologic ,IHC , molecular features
differentiation based on
the myoinvasive growth pattern
and LVI
ESN :
 Rare ,benign
 Premenopausal
 Presentation – abnormal bleeding or abdominal or pelvic
pain
 10% - asymptomatic
 Gross – well circumscribed
non encapsulated
fleshy yellow to tan nodule
 Location – myometrium ,protruding into endometrium
 Infarct type necrosis – 60%
 Cyst formation – 30%
CD 10+
Microscopic :
 Expansile
 non infiltrative border
 Compresses surrounding myometrium and
endometrium
 Has finger like projections into myometrium
Length -3mm
Number < 3
 If length >3mm
number > 3
LVI +
 satellite nodules
focal infiltrative growth
Treatment :
 Hysterectomy only– Benign
 Follow up
Low grade ESS
ESN with
limited invasion
LGESS
 History and presentation same as ESN
 Premenopausal
 Intial presentation – mostly intrauterine
rarely with metastasis to lungs and ovaries
 lymph node metastasis – 10%
 Gross – involves endometrium
soft ,tan to yellow polyp- infarcted/haemorrhagic
Invades myometrium
Microscopic :
 Formation of irregular , pink ,tan yellow cords or
nodules of tumor
 Involves endometrium and infiltrates myometrium as
irregular tongues with LVI
 Well differentiated endometrial stromal cells
 Mild nuclear atypia
 Necrosis rare
IHC :
 ER+ PR+ Androgen + WT-1 +
 CD 10 ++
 Smooth muscle actin +
 Desmin less positive,30%
 Negative – HDAC8 , H caldesmin
 Nuclear Beta catenin + in 40% of cases
Cytogenetics :
 The most common translocation involves the short arm of
chromosome 7 and the long arm of chromosome 17 [t(7;17)] leading
to fusion of two zinc finger genes, JAZF1 and JJAZ1 (also referred to
as SUZ12), and the production of the JAZF1/JJAZ1 gene fusion
protein.
 This is characteristic of ESS
 Function of JAZF1, JJAZ1, or the JAZF1/JJAZ1 gene fusion has not
been determined; however, in cultured cells, the fusion gene appears to
modulate cell survival and proliferation
 Other gene fusion proteins :
t(6;7) JAZF1/PHF1
t(6;10) EPC1/PHF1
Nature : LGESS
 low grade
 Favorable prognosis
 Stage is prognostic
STAGE 5Yr survival
I, II 90%
III, IV 50%
Course :
 Indolent
 Late recurrences – early stage – 36-56% recurrences
 Median time for recurrence – stage I-65months
stage III,IV -9 months
High Grade ESS :
 Features between low grade ESS and undifferentiated
 Age -28-67yrs
 Presentation – abnormal vaginal bleeding
enlarged uterus
pelvic mass
 Gross – intracavitatory polypoid
and pelvic mass
size upto 9cm
 Shows extrauterine extension at time
Of diagnosis
Cut section :
 Fleshy with extensive areas of necrosis and haemorrhage
Microscopic:
 High grade round cells with low grade spindle cell
component – fibromyxoid
 Mitotic activity - >10/10HPF
 Necrosis +
IHC :
 C Kit +
ER - PR - CD 10 -
CYCLIN D1 ++
Cytogenetics :
 The t(10;17) rearrangement results in a 14-3-3 fusion to
FAM22 (known as YWHAE-FAM22), leading to
aberrant localization of 14-3-3 in the nucleus and
possible oncogenic transformation
 is associated with a high-grade variant of ESS
 Clinically more aggressive and carries a worse prognosis
 However, it does not display prominent nuclear
pleomorphism, which is generally seen with UES
Undifferentiated :
 Heterogeneous group of sarcomas lacking diagnostic
criteria for:
ESS
LMS
Adenosarcoma with sarcomatous overgrowth
Carcinosarcoma/poorly differentiated carcinoma
 UES also expresses the receptor tyrosine kinase CD117
(c-KIT) and human epidermal growth factor receptor 2
(HER2 or ERBB2), which are not typically found in ESS.
 Unlike ESS, there are no known chromosomal
abnormalities associated with UES.
 Rare
 Post menopausal -60yrs
 Presentation : post menopausal bleeding
complaints secondary to extra-uterine disease
 Usual presentation with Stage III,IV disease
UES is always a
diagnosis of exclusion
Microscopic :
 Myometrial invasion
 Nuclear pleomorphism
 High mitotic activity
 Tumor cell necrosis
lack smooth muscle or endometrial stromal
differentiation
 They lack the typical growth pattern and vascularity of
low grade ESS and displace the myometrium in contrast
to the infiltrative pattern of low grade ESS
Uniform type Pleomorphic type
Imaging :
• Ultrasound—non specific
typically characterized as a heterogeneous
hypoechoic endometrial mass, which can show
extensive myometrial involvement
larger size, more contrast enhancement, irregular margin,
nodular extension into the myometrium, and marginal
nodularity due to tumor extension along vessels and
lymphatics
Staging :FIGO 2009
Diagnosis
BIOPSY POST HYSTERECTOMY
• Baseline imaging
• Confined to uterus– TAH+BSO
• Extra uterine disease +
Maximal Cytoreduction
NO MORCELLATION
NO Ovary Sparing
• Baseline imaging
• No second surgery
for staging
2
Role of Cytoreduction !!!
• High-grade ESS,
<2 cm of residual disease -- longer median OS –
52 versus 2 months
• Low grade ESS – No clear role
 older patients
 black race
 advanced stage
 higher grade
 lack of primary surgery,
 nodal metastasis
Adjuvant Therapy :
 ESN – None
 Low grade ESS –
Stage I –observation
Stage II-IV – hormonal therapy
Radiotherapy can be given to reduce local
recurrences
 High grade ESS and Undiferrentiated ESS
Adjuvant therapy to be given in all stages
Low Grade ESS :
no significant differences in the rate of recurrence
between surveillance vs. adjuvant RT vs. progestin
therapy
STAGE 5yr OS 10yr OS
I 84% 77%
II 62% 49%
III 58% -
IV 37% -
STAGE I
Hormonal Therapy
 Only in Low grade ESS
Options :
 Progestins--megestrol/medroxy progesterone
 Aromatase inhibitors– Letrozole/Anastrazole
 Gnrh Analogues
Tamoxifen, as well as hormonal replacement
therapy containing estrogens are contraindicated in
patients after treatment of ESS
Basis :
Primary ESS
ER α
PR α
PR β
ERα
ERβ
PRα
PRβ
STEROIDS
Proliferation and
Differentiation of
endometrial
Stromal cells
Normal endometrium
Recurrent ESS
ER α
PR α
PRβ
Progestin's -- antiestrogenic activity after binding to progesterone
receptor
Medroxyprogesterone acetate (MPA)(250mg daily)
Megestrole acetate (160mg daily)
• Side effects :
dramatic weight gain related to glucocorticoid activity, severe depression
and thrombo- embolic complications
• Aromatase inhibitors :-- reduce estrogen levels by
inhibiting estrogen synthesis in peripheral sites and tumor
tissues, which leads to reduced receptor-mediated growth
stimulation
1st generation—aminoglutethemide
2nd generation—formestan,fadrozol
3rdgen. –nonsteroidal -- exesmestane(25mgday)
letrozole(2.5mg/day)
steroidal– anastrazole(1mg/day)
• Gnrh Analogues :-they suppress ovarian estrogen
production.
additional growth inhibitory effect via intratumoral
modulation of mitogenic signaling of growth factor receptors
leuprolide, gosereline, triptorelin
Drug of choice –Aromatase inhibitor
Cytotoxic chemotherapy:
ifosfamide , doxorubicin –most active
 Hormonal options is exhausted
 in the absence of hormonal receptors
 when progression into a high-grade malignancy
occurs
Duration???
Radiotherapy???
Radiotherapy helps to improve local control
Can be given in stage II-IV ESS
ESS :
 Sampath et al.--showed a significant decrease in 5-
year local–regional recurrence rate
 Most studies--improvement in local control with
adjuvant radiotherapy
Undifferentiated ESS:
 Poor OS regardless of stage
 Due to high risk of recurrence
regardless of stage , adjuvant
chemotherapy should be given to all patients with
UES.
 Combination regimen eg: gemcitabine plus
docetaxel is preferred
STAGE MEDIAN PFS MEDIAN OS
I 15months 27months
II-IV 7months 12months
Follow Up : NCCN
• physical exam every three months for the first
two years and then every 6 to 12 months.
• CT scans of the chest, abdomen, and pelvis
every 6 to 12 months (or as clinically
indicated) for the first five years
• Long term surveillance with CT scans
shouldn't be done.
Recurrent disease :
 abdomen/pelvis (40 to 50 %)
 lung ( 25 %)
 Rare- spine
 Treatment naïve --- hormone therapy
• Recurrent disease post
treatment
• Metastatic disease
Cytotoxic
chemotherapy
STAGE MEDIAN
TIME
I AND II 65 months
III AND IV 9 months
Carcinosarcoma
Mixed epithelial and mesenchymal
tumours :
Tumours of the uterine corpus composed of an epithelial
and a mesenchymal component.
 Carcinosarcoma **
 Adenosarcoma
 Carcinofibroma
 Adenofibroma
 Adenomyoma
Atypical polypoid variant
Carcinosarcoma(MMMT)
 composed of an admixture of malignant epithelial and
mesenchymal components.
 <5 percent of all uterine malignancies
 7th decade
 Most common among sarcomas
 Risk factors : obesity , diabetes , nulliparity,tamoxifen
prior pelvic radiation
 Presentation : vaginal bleeding >abdominal mass>pelvic
pain
 Examination : polypoid mass protruding through cervix
and presents as upper vaginal mass
There are 4 main theories regarding the histogenesis of CS:
(1) the collision theory,
(2) the combination theory,
(3) the conversion theory
(4) the composition theory .
Now its clear that CS arises through
conversion and metaplasia
Dedifferentiated or Metaplastic endometrial
carcinoma
Imaging :
 Ultrasound - hyperechoic compared with the
myometrium. In addition, expansion of the
endometrial canal is seen
• CT scan —a heterogenous, ill defined, hypodense
mass with concomitant
dilatation of the
endometrial canal..
MRI :
 enlarged uterus with a widened endometrial cavity and
evidence of deep myometrial invasion.
 Heterogenous bulky mass protruding into cervix
 Prolonged intense enhancement
CT
 FDG PET/CT –useful for diagnostic and initial
staging purposes. CS is generally positive on PET
scan; the mean standardized uptake value (SUV) of
10+/-5.5
 CA-125:
 Preoperative CA125 elevation is a marker of
extrauterine disease and deep myometrial invasion.
 Postoperative CA125 elevation is an independent
prognostic factor for poor survival
Macroscopic :
Polypoid , bulky, necrotic and
hemorrhagic filling endometrium
and invading myometrium
Epithelial Mesenchymal
Glandular Non glandular Homologous Heterologous
endometroid squamous Undifferentiated
Endometrial
sarcoma
Rhabdomyosarc
oma
serous undifferentiated Leiomyosarcoma chondrosarcoma
Clear cell ESS liposarcoma
Microscopic – Biphasic
• Most common combination :
high-grade serous carcinoma and an endometrial stromal sarcoma
Uterine carcinosarcoma is a histologic
diagnosis
IHC : epithelial—anticytokeratin + mesenchymal –vimentin +
Staging :FIGO 2009
Treatment :
 Complete surgery -- total hysterectomy, bilateral
salpingo-oophorectomy, pelvic and para-aortic
lymph node dissection, cytology of peritoneal
washings, omentectomy, and biopsies of
peritoneal surfaces
• Lymphadenectomy is significantly associated with
improved overall survival in patients with Stage I-
III uterine carcinosarcoma
• No survival benefit with radiotherapy
Adjuvant therapy :
Stage Ia :
 No trials have evaluated the value of adjuvant
chemotherapy specifically in women with stage
IA disease
 GOG 20– adjuvant doxorubicin vs surveillance.
Low recurrence rates
 GOG 55874- Adjuvant RT vs surveillance
low local recurrence
Stage IB-IV :
 Adjuvant chemotherapy is preferred rather
than RT or observation .
Local relapse-- 44%-24%
 whole abdominal- pelvic irradiation - 30.6 Gy to the whole
abdomen and pelvis, f/b a 19.8 Gy pelvic boost or three cycles
of cisplatin, ifosfamide and mesna (CIM)
 No statistically significant difference was found in OS (45%
CIM v 35% WAI) or DFS---58% WAI v 52% CIM
 WAI led to a decline - vaginal failures (4% v 10%),
no difference in pelvic failures (13%).
 Estimated 5yr survival– 35% (WAI) vs 45% ( chemotherapy)
 Adjuvant radiotherapy –more late complications
Uncertain Role
Chemotherapy regimen:
Single Agent Chemotherapy :
 Ifosfamide (36%)
• etoposide (6.5%)
• doxorubicin (9.8%)
• cisplatin (18%)
• paclitaxel (18%)
• topotecan (10%)
The regimen of chemotherapy recommended for
use in early stage disease is the same as for late
stage disease
GOG trials for Carcinosarcoma:
GOG 261, a Phase 3 randomized trial of
ifosfamide and paclitaxel versus carboplatin
and paclitaxel is ongoing…
Role of radiotherapy!!!
• Smith et al. & Nemani et al.—no survival benefit
associated with adjuvant radiotherapy in stage I–III
carcinosarcoma,
• whereas Smith et al-- overall survival benefit -stage IV
disease
• Sampath et al.-decrease in local failure
no change in overall survival
EORTC : GCG 55874 study –CS
• 224 patients –LMS(99), CS(92), and ESS(30).
• External beam pelvic radiotherapy with observation in
FIGO stage I and II disease .
• With a median follow- up of 6.8 years, no difference was
found in overall survival or disease-free survival .
pelvic recurrences local recurrences
Surgery alone 24% 47%
Surgery + RT 4% 24%
Rare Sarcomas :
 Adenosarcoma
 PEComa
 Rhabdomyosarcoma
Adenosarcoma :
 Mixed tumor of low malignant potential
 Benign glandular elements +low grade sarcoma
 5-10% of all sarcomas
 all ages, ranging from 15-90 years --median age at
diagnosis of 58.
 Risk factors :tamoxifen therapy for breast cancer
prior pelvic radiation
 Origin : endometrium in lower uterine segment
rare-endocervix
 Presentation :abnormal vaginal bleeding, an enlarged
uterus and tissue protruding from the external os
Gross :
polypoid tumors of approximately 5–6 cm in maximum
diameter (range, 1–20 cm) that typically fill and distend
the uterine cavity
Cut section –
• tan brown with foci of
haemorrhage and necrosis.
• Small cysts
• mostly do not invade
myometrium
Microscopic :
 Periglandular cuffs—stroma
concentrates around glands
 Mild nuclear atypia
 Few or no mitosis
 Mesenchymal elements -10-
15% cases
• Adenosarcoma With Sarcomatoid Overgrowth :
Pure sarcomatous component >25% of total tumor volume
• IHC : CD 10+
PR+
Ki 67+
cytokeratins
FIGO staging 2009 :
 low grade
 Recurs --25-40% of cases, typically in the pelvis or
vagina, and distant metastasis 5%
 Poor prognostic -- extrauterine spread,
deep myometrial invasion
sarcomatous overgrowth.
Vascular invasion
 Long- term follow-up is necessary because recurrences
may manifest after many years.
TREATMENT :
 TAH+BSO
 If sarcomatous overgrowth – adjuvant pelvic
radiotherapy.
PEComa(Perivascular epithelioid
cell tumor):
 Poorly defined, rare tumors characterized by varying
amounts of epithelioid and spindle cells with clear to
eosinophilic, granular cytoplasm that is HMB45+ in a
diffuse or focal pattern
 Mean age of 45 years (range, 9 - 79 years)
 ~50 cases reported in English language literature
 Sites-uterus and retroperitoneum
 2 types – Benign & Malignant
 Etiology unknown
 Aggresive in nature and recurs post hysterectomy
Gross:
 polypoid mass
 Solitary or rarely multifocal mass in uterine
corpus from 0.6 to 12.0 cm (mean of 4.7 cm)
 Cut sections may be grayish white, tan or
yellow with whorled or soft, fleshy, ill defined
or rarely circumscribed margins
BENIGN:
• tongue-like growth pattern similar to LGESS;
• well defined cell borders, abundant granular or clear to
eosinophilic cytoplasm,
• Usually no / mild pleomorphism.no mitotic figures,no necrosis
• Strong, diffuse cytoplasmic HMB45 expression and focal
muscle marker expression
Microscopic : BENIGN OR MALIGNANT
Malignant :
 diffuse sheets of cells, separately by occasional small,
hyalinized bundles and plaques of stroma;
 contain primarily perivascular epithelioid cells (> 50% are
round or polygonal)
 focal HMB45 expression, and
 strong, extensive muscle marker expression
 malignant features include mitotic activity > 1/10 HPF,
necrosis, tumor size > 5 cm, infiltrative growth pattern, high
nuclear grade, cytologic atypia, high cellularity,
lymphovascular invasion, infiltration
Positive Stains :
 HMB45, SMA (73%), p53 (50%), melanA / MART1
(24% - 67%)
 Also calponin, vimentin, h-caldesmon; PR (50%),
desmin (49%), muscle specific actin (36%), ER (33%),
CD10 (25%)
Treatment :
Hysterectomy, with or without adjuvant chemotherapy and
radiotherapy
Rhabdomyosarcoma :
 Pure rhabdomyosarcoma arising in the uterus is a very
rare tumor
 mainly in elderly women,
 highly malignant tumors with frequent extrauterine
spread at presentation.
 Patients rarely survive beyond 15 months.
 uterine cervix and corpus are the most frequent locations
of RMS in adult women.
 Three categories: embryonal, alveolar, and pleomorphic
 In postmenopausal women, uterine RMSs appear to be
entirely the pleomorphic type with extremely poor
clinical outcome.
 The median progression-free survival (PFS) and disease-
specific survival was 9 months and 21 months respectively.
 The 5- year disease-specific survival was only 29%
Radiotherapy practice:
 No role of upfront Radiotherapy
 It is given in adjuvant settings post surgery
Indications :
 High grade and undifferentiated endometrial sarcomas
 Adenosarcomas, especially with sarcomatous
overgrowth.
 Carcinosarcomas
early-stage comprehensively staged patients,
intravaginal RT and chemotherapy
stage III concurrent pelvic RT and cisplatin followed
by carboplatin/paclitaxel.
Technique :
 CT based planning with CT taken with
full bladder
PTV final = ITV Vault + PTV total
Dose to PTV final : 50Gy/25#/5wks
 In case of carcinosarcoma
We usually give Radiotherapy in a sandwich
pattern with chemotherapy
Chemotherapy in practice:
 LMS
 High grade ESS
 Carcinosarcoma – Inj paclitaxel 175mg/m2
Inj carboplatin 5 AUC
 Low grade ESS – Letrozole 2.5mg OD
IAP 3 weekly for 6 cycles
Inj ifosfamide 1.2gm/m2
Inj adriamycin 20mg/m2
Inj Cisplatin 50mg/m2
Targeted Treatment :
• Retrospective review of medical records of patients of uterine sarcoma
(20022007)
• 42 (15 CS, 12 ESS, 11 LMS, 3 UES, and 1 mixed sarcoma
• Adjuvant radiation, chemoradiation, and chemotherapy were offered.
Pelvic radiation: 46 Gray/23 fractions/4.5 weeks and vincristine,
adriamycin, cyclophosphamide (VAC) regimen were most commonly used
• Median OS of only 6.57, 6.8, and 9.38 months, respectively, in patients
with carcinosarcoma, leiomyosarcoma, and UES
• Disease stage (p = 0.005) and response to therapy (p = 0.01)—predictors of
OS
• Small series, poor treatment compliance and socioeconomic constraints in
the indian scenario were the limiting factors
Conclusion :
 Uterine sarcomas are very aggressive neoplasms
 No imaging modality can offer a reliable preoperative
diagnosis
 As a result, centralisation, large series, and randomised
trials are problematic.
 Aggressive surgical cytoreduction at the time of initial
diagnosis offers the best survival
 To date, no effective adjuvant therapy has been found to
prolong the survival of women with uterine sarcomas.
 More RCTs are needed to determine the value and
regime of adjuvant therapy
Thank you…

More Related Content

What's hot

Ovarian tumors by mahmoud kareem
Ovarian tumors by mahmoud kareemOvarian tumors by mahmoud kareem
Ovarian tumors by mahmoud kareem
mahmoud kareem
 
Endometrial cancer recommendations
Endometrial cancer recommendationsEndometrial cancer recommendations
Endometrial cancer recommendations
LAKSHMI DEEPTHI GEDELA
 
germ cell tumours of ovary
germ cell tumours of ovarygerm cell tumours of ovary
germ cell tumours of ovary
Sreelasya Kakarla
 
Breast Cancer during pregnancy
Breast Cancer during pregnancyBreast Cancer during pregnancy
Breast Cancer during pregnancySaeed Al-Shomimi
 
Carcinoma Endometrium
Carcinoma  EndometriumCarcinoma  Endometrium
Carcinoma Endometriumdrmcbansal
 
Treatment of uterine sarcoma
Treatment of uterine sarcomaTreatment of uterine sarcoma
Treatment of uterine sarcoma
WonduBelayneh
 
Management of carcinoma cervix
Management of carcinoma cervixManagement of carcinoma cervix
Management of carcinoma cervix
Varshu Goel
 
FIGO 2014 Staging of Cancer Ovary
FIGO 2014 Staging of Cancer OvaryFIGO 2014 Staging of Cancer Ovary
FIGO 2014 Staging of Cancer Ovary
Sujoy Dasgupta
 
Ovarian Carcinoma
Ovarian CarcinomaOvarian Carcinoma
Ovarian Carcinoma
FAISALKHAN900
 
Benign ovarian masses
Benign ovarian masses Benign ovarian masses
Benign ovarian masses
Ayesha Safi
 
Carcinoma vagina
Carcinoma vaginaCarcinoma vagina
Carcinoma vagina
Nabeel Yahiya
 
Carcinoma Endometrium DR H.K.Cheema Professor-OBG,PIMS Jalandhar
Carcinoma Endometrium   DR H.K.Cheema Professor-OBG,PIMS JalandharCarcinoma Endometrium   DR H.K.Cheema Professor-OBG,PIMS Jalandhar
Carcinoma Endometrium DR H.K.Cheema Professor-OBG,PIMS Jalandhar
Dr H.K. Cheema
 
Portec trial ppt
Portec trial pptPortec trial ppt
Portec trial ppt
Sailendra Parida
 
Recurrent ovarian cancer
Recurrent ovarian cancerRecurrent ovarian cancer
Recurrent ovarian cancer
Shruthi Shivdas
 
Ovarian Cancer
Ovarian CancerOvarian Cancer
Portec 4a
Portec 4aPortec 4a
Portec 4a
Shruthi Shivdas
 
Radiation for Cervix Cancer
Radiation for Cervix CancerRadiation for Cervix Cancer
Radiation for Cervix Cancer
Robert J Miller MD
 
Ovarian classification and Management
Ovarian classification and ManagementOvarian classification and Management
Ovarian classification and Management
Sourav Chowdhury
 
DCIS Breast Cancer
DCIS Breast CancerDCIS Breast Cancer
DCIS Breast Cancer
Robert J Miller MD
 
Carcinoma Vulva
Carcinoma VulvaCarcinoma Vulva
Carcinoma Vulvadrmcbansal
 

What's hot (20)

Ovarian tumors by mahmoud kareem
Ovarian tumors by mahmoud kareemOvarian tumors by mahmoud kareem
Ovarian tumors by mahmoud kareem
 
Endometrial cancer recommendations
Endometrial cancer recommendationsEndometrial cancer recommendations
Endometrial cancer recommendations
 
germ cell tumours of ovary
germ cell tumours of ovarygerm cell tumours of ovary
germ cell tumours of ovary
 
Breast Cancer during pregnancy
Breast Cancer during pregnancyBreast Cancer during pregnancy
Breast Cancer during pregnancy
 
Carcinoma Endometrium
Carcinoma  EndometriumCarcinoma  Endometrium
Carcinoma Endometrium
 
Treatment of uterine sarcoma
Treatment of uterine sarcomaTreatment of uterine sarcoma
Treatment of uterine sarcoma
 
Management of carcinoma cervix
Management of carcinoma cervixManagement of carcinoma cervix
Management of carcinoma cervix
 
FIGO 2014 Staging of Cancer Ovary
FIGO 2014 Staging of Cancer OvaryFIGO 2014 Staging of Cancer Ovary
FIGO 2014 Staging of Cancer Ovary
 
Ovarian Carcinoma
Ovarian CarcinomaOvarian Carcinoma
Ovarian Carcinoma
 
Benign ovarian masses
Benign ovarian masses Benign ovarian masses
Benign ovarian masses
 
Carcinoma vagina
Carcinoma vaginaCarcinoma vagina
Carcinoma vagina
 
Carcinoma Endometrium DR H.K.Cheema Professor-OBG,PIMS Jalandhar
Carcinoma Endometrium   DR H.K.Cheema Professor-OBG,PIMS JalandharCarcinoma Endometrium   DR H.K.Cheema Professor-OBG,PIMS Jalandhar
Carcinoma Endometrium DR H.K.Cheema Professor-OBG,PIMS Jalandhar
 
Portec trial ppt
Portec trial pptPortec trial ppt
Portec trial ppt
 
Recurrent ovarian cancer
Recurrent ovarian cancerRecurrent ovarian cancer
Recurrent ovarian cancer
 
Ovarian Cancer
Ovarian CancerOvarian Cancer
Ovarian Cancer
 
Portec 4a
Portec 4aPortec 4a
Portec 4a
 
Radiation for Cervix Cancer
Radiation for Cervix CancerRadiation for Cervix Cancer
Radiation for Cervix Cancer
 
Ovarian classification and Management
Ovarian classification and ManagementOvarian classification and Management
Ovarian classification and Management
 
DCIS Breast Cancer
DCIS Breast CancerDCIS Breast Cancer
DCIS Breast Cancer
 
Carcinoma Vulva
Carcinoma VulvaCarcinoma Vulva
Carcinoma Vulva
 

Similar to Uterine sarcoma mine

Soft tissue sarcomas
Soft tissue sarcomasSoft tissue sarcomas
Soft tissue sarcomas
Ankit Sharma
 
Testicular cancer
Testicular cancerTesticular cancer
Testicular cancer
Kiron G
 
Cancergastritis200810
Cancergastritis200810Cancergastritis200810
Cancergastritis200810
subhayanmandal
 
Testicular tumor final
Testicular tumor finalTesticular tumor final
Testicular tumor final
Abdul Haleem
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcomaArun Raj
 
TD Vac.pptx
TD Vac.pptxTD Vac.pptx
TD Vac.pptx
AnnaMag3
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcoma
Silah Aysha
 
MBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptx
MBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptxMBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptx
MBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptx
MohanSinghDhakad1
 
Ewing’s sarcoma
Ewing’s sarcomaEwing’s sarcoma
Ewing’s sarcoma
ManishShrestha51
 
Testicular tumors-Cassification, Biomarkers and Staging by Dr Rajesh
Testicular tumors-Cassification, Biomarkers and Staging by Dr RajeshTesticular tumors-Cassification, Biomarkers and Staging by Dr Rajesh
Testicular tumors-Cassification, Biomarkers and Staging by Dr Rajesh
Rajesh Sinwer
 
Uterine sarcoma
Uterine sarcoma Uterine sarcoma
Uterine sarcoma
Beena K
 
Testicular tumor
Testicular tumorTesticular tumor
Testicular tumor
Faryal Tebani
 
MDT conference case
MDT conference caseMDT conference case
MDT conference case
imrana tanvir
 
Ca breast final
Ca breast finalCa breast final
Ca breast final
Kirti Dixit
 
Management of malignant spinal cord compression
Management of malignant spinal cord compressionManagement of malignant spinal cord compression
Management of malignant spinal cord compression
Shreya Singh
 
Neoplasia & Carcinogenesis
Neoplasia & CarcinogenesisNeoplasia & Carcinogenesis
Neoplasia & CarcinogenesisMuhammad Helmi
 
Carcinoma breast clinical pathology dr mnr
Carcinoma breast clinical pathology dr mnrCarcinoma breast clinical pathology dr mnr
Carcinoma breast clinical pathology dr mnr
SREE GOKULAM MEDICAL COLLEGE AND RESEARCH FOUNDATION
 
Discuss the pathology of bladder cancers
Discuss the pathology of bladder cancersDiscuss the pathology of bladder cancers
Discuss the pathology of bladder cancers
Jim Badmus
 
Treatment for cancer
Treatment for cancerTreatment for cancer
Treatment for cancer
Md.Mustahasin Karim
 

Similar to Uterine sarcoma mine (20)

Soft tissue sarcomas
Soft tissue sarcomasSoft tissue sarcomas
Soft tissue sarcomas
 
Testicular cancer
Testicular cancerTesticular cancer
Testicular cancer
 
Cancergastritis200810
Cancergastritis200810Cancergastritis200810
Cancergastritis200810
 
Testicular tumor final
Testicular tumor finalTesticular tumor final
Testicular tumor final
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcoma
 
TD Vac.pptx
TD Vac.pptxTD Vac.pptx
TD Vac.pptx
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcoma
 
MBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptx
MBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptxMBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptx
MBBS Class. Testicular tumor. BPSingh.Urology.11.10.2014.pptx
 
Ewing’s sarcoma
Ewing’s sarcomaEwing’s sarcoma
Ewing’s sarcoma
 
Testicular tumors-Cassification, Biomarkers and Staging by Dr Rajesh
Testicular tumors-Cassification, Biomarkers and Staging by Dr RajeshTesticular tumors-Cassification, Biomarkers and Staging by Dr Rajesh
Testicular tumors-Cassification, Biomarkers and Staging by Dr Rajesh
 
Uterine sarcoma
Uterine sarcoma Uterine sarcoma
Uterine sarcoma
 
Testicular tumor
Testicular tumorTesticular tumor
Testicular tumor
 
MDT conference case
MDT conference caseMDT conference case
MDT conference case
 
Ca breast final
Ca breast finalCa breast final
Ca breast final
 
Management of malignant spinal cord compression
Management of malignant spinal cord compressionManagement of malignant spinal cord compression
Management of malignant spinal cord compression
 
Neoplasia & Carcinogenesis
Neoplasia & CarcinogenesisNeoplasia & Carcinogenesis
Neoplasia & Carcinogenesis
 
Mr Mammography New
Mr Mammography NewMr Mammography New
Mr Mammography New
 
Carcinoma breast clinical pathology dr mnr
Carcinoma breast clinical pathology dr mnrCarcinoma breast clinical pathology dr mnr
Carcinoma breast clinical pathology dr mnr
 
Discuss the pathology of bladder cancers
Discuss the pathology of bladder cancersDiscuss the pathology of bladder cancers
Discuss the pathology of bladder cancers
 
Treatment for cancer
Treatment for cancerTreatment for cancer
Treatment for cancer
 

More from LAKSHMI DEEPTHI GEDELA

Microtubule inhibitors
Microtubule inhibitorsMicrotubule inhibitors
Microtubule inhibitors
LAKSHMI DEEPTHI GEDELA
 
Primary cns lymphoma main
Primary cns lymphoma mainPrimary cns lymphoma main
Primary cns lymphoma main
LAKSHMI DEEPTHI GEDELA
 
Journal ribo
Journal ribo Journal ribo
Journal ribo
LAKSHMI DEEPTHI GEDELA
 
Journal auto bmt
Journal auto bmtJournal auto bmt
Journal auto bmt
LAKSHMI DEEPTHI GEDELA
 
Hr+ mbc
Hr+ mbc Hr+ mbc
Hormonal therapy breast mine
Hormonal therapy breast mineHormonal therapy breast mine
Hormonal therapy breast mine
LAKSHMI DEEPTHI GEDELA
 
Hodgkins lymphoma treat
Hodgkins lymphoma treatHodgkins lymphoma treat
Hodgkins lymphoma treat
LAKSHMI DEEPTHI GEDELA
 
Journal alternative
Journal alternativeJournal alternative
Journal alternative
LAKSHMI DEEPTHI GEDELA
 
Physical factors carcino
Physical factors carcinoPhysical factors carcino
Physical factors carcino
LAKSHMI DEEPTHI GEDELA
 
Pharmacogenomics mine
Pharmacogenomics minePharmacogenomics mine
Pharmacogenomics mine
LAKSHMI DEEPTHI GEDELA
 
Angiogenesis
AngiogenesisAngiogenesis
Aml flt3 itd
Aml flt3 itdAml flt3 itd
Surgery in cancer prevention
Surgery in cancer preventionSurgery in cancer prevention
Surgery in cancer prevention
LAKSHMI DEEPTHI GEDELA
 
Platinum analogs
Platinum analogsPlatinum analogs
Platinum analogs
LAKSHMI DEEPTHI GEDELA
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodies
LAKSHMI DEEPTHI GEDELA
 
Prostate ca
Prostate caProstate ca
Ppt.cns radiobiology
Ppt.cns radiobiologyPpt.cns radiobiology
Ppt.cns radiobiology
LAKSHMI DEEPTHI GEDELA
 
Breast screening
Breast screeningBreast screening
Breast screening
LAKSHMI DEEPTHI GEDELA
 

More from LAKSHMI DEEPTHI GEDELA (20)

Microtubule inhibitors
Microtubule inhibitorsMicrotubule inhibitors
Microtubule inhibitors
 
Primary cns lymphoma main
Primary cns lymphoma mainPrimary cns lymphoma main
Primary cns lymphoma main
 
Journal ribo
Journal ribo Journal ribo
Journal ribo
 
Journal auto bmt
Journal auto bmtJournal auto bmt
Journal auto bmt
 
Hr+ mbc
Hr+ mbc Hr+ mbc
Hr+ mbc
 
Hormonal therapy breast mine
Hormonal therapy breast mineHormonal therapy breast mine
Hormonal therapy breast mine
 
Hodgkins lymphoma treat
Hodgkins lymphoma treatHodgkins lymphoma treat
Hodgkins lymphoma treat
 
Gist
GistGist
Gist
 
Journal alternative
Journal alternativeJournal alternative
Journal alternative
 
Physical factors carcino
Physical factors carcinoPhysical factors carcino
Physical factors carcino
 
Pharmacogenomics mine
Pharmacogenomics minePharmacogenomics mine
Pharmacogenomics mine
 
Angiogenesis
AngiogenesisAngiogenesis
Angiogenesis
 
Aml flt3 itd
Aml flt3 itdAml flt3 itd
Aml flt3 itd
 
Surgery in cancer prevention
Surgery in cancer preventionSurgery in cancer prevention
Surgery in cancer prevention
 
Screening
ScreeningScreening
Screening
 
Platinum analogs
Platinum analogsPlatinum analogs
Platinum analogs
 
Monoclonal antibodies
Monoclonal antibodiesMonoclonal antibodies
Monoclonal antibodies
 
Prostate ca
Prostate caProstate ca
Prostate ca
 
Ppt.cns radiobiology
Ppt.cns radiobiologyPpt.cns radiobiology
Ppt.cns radiobiology
 
Breast screening
Breast screeningBreast screening
Breast screening
 

Recently uploaded

THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 

Recently uploaded (20)

THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 

Uterine sarcoma mine

  • 2. Sarcoma : ( sarx -"flesh") is a cancer that arises from transformed cells of mesenchymal origin Uterine sarcomas arise from dividing cell populations in the myometrium or connective tissue elements within the endometrium Uterine sarcomas : 1% of female genital tract cancers 3-7% of uterine cancers
  • 5. Uterine Sarcoma Classification : NCCN 2016 • Low grade endometrial stromal sarcoma(ESS) • High grade ESS • Undifferentiated Uterine Sarcoma(UUS) • Uterine Leiomyosarcoma (uLMS) Other Rare Uterine Mesenchymal Sarcoma Subtypes : • Adenosarcoma • PEComas • Rhabdomyosarcoma
  • 6.
  • 7. General Features :  Each group of tumors is distinct with respect to pattern of spread, pathologic features, prognostic factors and response to treatment.  Incidence : carcinosarcomas (45%) > leiomyosarcomas, (40%) > endometrial stromal sarcomas(15%)  Age-related incidences vary among the histologic types. The mean age at diagnosis for endometrial stromal sarcoma is 41 years, for leiomyosarcoma 53.5 years, for adenosarcoma 57.4 years, and for carcinosarcoma 65 years  Staging system different for each Leiomyosarcoma and ESS Adenosarcoma Carcinosarcoma
  • 8. Rare sarcomas  Clinical features  Pathology  Diagnostic workup  Treatment • Leiomyosarcoma • ESS • Carcinosarcoma
  • 9. Leiomyosarcoma malignant neoplasm composed of cells demonstrating smooth muscle differentiation true sarcomas  1-2% of all uterine tumors  30% of all uterine sarcomas  >40yrs of age  Presentation : vaginal bleeding (56%) pelvic mass(54%) pelvic pain (22%)
  • 10. Diagnosis:  Preoperative– endometrial sampling pelvic ultrasound MRI CT chest  Postoperative – ---No second surgical procedure for the sole purpose of staging. ---postop CT of the chest, abdomen, and pelvis.
  • 11.  Pelvic ultrasound is typically the first-line study  S/o sarcoma --mixed echogenic and poor echogenic parts; central necrosis  Color Doppler -- irregular vessel distribution, low impedance to flow, and high peak systolic velocity  CT does not reliably differentiate between leiomyomas and uterine sarcomas
  • 12. T1 MR T2 MR • MRI vary and include a lobulated mass of high-signal intensity on T2- weighted images, • scattered foci of haemorrhages or necrosis • These necrotic areas are -- slightly higher intensity on T1-weighted images and as heterogeneous areas on T2-weighted images. • A consistent finding -- the absence of calcifications.
  • 13. Pathology : Gross:  solitary intramural masses  Average 8cm in diameter  fleshy with poorly defined margins.  Cut section : typically soft, bulging, fleshy, necrotic, hemorrhagic, and lacks the prominent whorled appearance of leiomyomas. Microscopic :Stanford criteria High nuclear atypia Coagulative necrosis High mitotic rate
  • 14. Variants : Epitheloid : Necrosis absent Mild nuclear atypia Less mitotic rate Myxoid : hypo cellular Mild nuclear atypia
  • 15. IHC :  Positive for smooth muscle markers Desmin ,H-Caldeson , actin, histone deacetylase 8  Epitheloid and myxoid variants are less immunoreactive  Epitheloid –keratin ,EMA positive  ER+,PR +,androgen receptor + --30-40 % of cases  Ki 67 increased  P16 overexpressed – differentiate between benign and malignant
  • 17. Total abdominal Hysterectomy +/- B/L Salpingo-oopherectomy TREATMENT Disease confined to uterus Disease extending outside uterus TAH with BSO and surgical cytoreduction of intra- abdominal and retroperitoneal disease
  • 18. Lymphadenectomy ???  If the pelvic nodes are palpably enlarged intraoperatively  there is evidence of extrauterine disease LN involvement <5% 1992
  • 19. Prognostic factors :  Tumor size (>10cm)  Mitotic rate (20 MF/10HPF)  Ki 67 (>10%)  Bcl 2 (Negative) Overall prognosis :  Poor even in stage I disease  Recurrence – 53-71% ---lungs -40% Pelvis – 13%  5yr survival – 15-25% of cases  Median survival – 10 months STAGE 5YR OS I 76% II 60% III 45% IV 29%
  • 20. Adjuvant Treatment :  Chemotherapy or Pelvic radiation can be considered following surgery for leiomyosarcoma (LMS).  However, whether any form of adjuvant therapy improves survival compared with observation is not known.  Early stage disease (I or II)– it is not clear if any intervention improves the survival outcomes compared with post-surgical surveillance. Observation is preferred
  • 21. Neither PFS, nor OS nor pelvic control was improved by radiotherapy. Therefore, radiation therapy is not indicated in patients with stage I or II LMS after complete resection
  • 22. Stage I or II sarcomas, varied histology • women treated with doxorubicin had a lower recurrence rate compared with those not treated with chemotherapy (41 versus 53 percent), this was not statistically significant. • In addition, adjuvant doxorubicin had no impact on progression-free or overall survival.
  • 23. • To estimate 2yr and 3yr PFS….n=46 • 4 cycles of gemcitabine plus docetaxel f/b 4 cycles of doxorubicin • 2yr PFS – 78% 3yr PFS – 57% • median time to recurrence was 27 month N=27 Single arm,phase II Completely resected I-IV2yr PFS-59% Median PFS -39months
  • 24. Advanced stage – Radiotherapy?? • Sampath et al.--significantly reduced local failure rate at 5 years of 2%, compared with 16% in the surgery-alone group
  • 25. NCCN– 2B Recommendation in LMS  high rates of initial metastatic failure in LMS  adjuvant pelvic radiotherapy does not appear to have a survival benefit in LMS,  although it may reduce local pelvic recurrences, possibly for disease that has spread beyond the uterus (FIGO stages II–IV) so might be considered for these higher risk women in order to improve local disease control.
  • 27.  chemotherapy with doxorubicin or docetaxel/gemcitabine is now used for advanced or recurrent disease, with response rates ranging from 27% to 36%
  • 28. • Early-stage --leiomyosarcoma, carcinosarcoma, and endometrial stromal sarcoma • CRT arm--increased 3-year DFS (55% vs 41%; P=0.048), • But no improvement in 3-year OS Combined Modality
  • 29. Metastatic or inoperable disease :  Palliative intent.  Chemotherapy --good performance status and in whom organ function permits the use of cytotoxic chemotherapy.  For other patients--palliative care  Doxorubicin-based treatment first-line choice.  Gemcitabine plus docetaxel--first- or second- line therapy
  • 30.
  • 31. Alternatives Or Second Line Therapy:  Doxorubicin based  Gemcitabine alone RR-20%  Ifosfamide alone – RR-17%  Ifosfamide + Doxorubicin – RR 30%  Trabectedin –progression on anthracyclines –ORR- 16%  Pazopanib  Erbulin  Endocrine Therapy– ORR<10%--Aromatase inhibitors can be considered for ER/PR- expressing uLMS
  • 32. Follow Up:  Physical exam every three to four months and chest, abdomen, and pelvic imaging every three to four months for two to three years,  every 6 to 12 months for the next two years. Recurrence
  • 33. STUMP :Smooth Muscle Tumors Of Uncertain Malignant Potential  Have high malignancy features but not falling into diagnostic criteria for leiomyosarcoma .  Microscopic : tumor cell necrosis necrosis of uncertain type >10 MF/10HPF diffuse atypia borderline mitotic counts  Favorable prognosis  Treatment – only follow up after total hysterectomy
  • 34. Endometrial Stromal Sarcoma • 0.2–1% of all uterine malignancies • 6–20% of all uterine sarcomas
  • 35. Norris and Taylor 1965 (old terminology)  Endometrial Stromal Nodule  Endometrial Stromal Sarcoma – Low grade (< 10 mits/10 hpf) High grade (>10 mits/10 hpf)  Undifferentiated Uterine Sarcoma Mitotic rate does not predict recurrence WHO Classification 2004
  • 36. WHO 2004  Endometrial Stromal Nodule  Endometrial Stromal Sarcoma (“low grade”)  Undifferentiated Uterine Sarcoma WHO 2014  Endometrial stromal nodule (ESN)  Low grade ESS  High grade ESS  Undifferentiated Cytogenetics
  • 37.  2nd most common mesenchymal uterine tumors (<10%)  ESN and low grade ESS are similar in morphologic ,IHC , molecular features differentiation based on the myoinvasive growth pattern and LVI
  • 38. ESN :  Rare ,benign  Premenopausal  Presentation – abnormal bleeding or abdominal or pelvic pain  10% - asymptomatic  Gross – well circumscribed non encapsulated fleshy yellow to tan nodule  Location – myometrium ,protruding into endometrium  Infarct type necrosis – 60%  Cyst formation – 30%
  • 39. CD 10+ Microscopic :  Expansile  non infiltrative border  Compresses surrounding myometrium and endometrium  Has finger like projections into myometrium Length -3mm Number < 3
  • 40.  If length >3mm number > 3 LVI +  satellite nodules focal infiltrative growth Treatment :  Hysterectomy only– Benign  Follow up Low grade ESS ESN with limited invasion
  • 41. LGESS  History and presentation same as ESN  Premenopausal  Intial presentation – mostly intrauterine rarely with metastasis to lungs and ovaries  lymph node metastasis – 10%  Gross – involves endometrium soft ,tan to yellow polyp- infarcted/haemorrhagic Invades myometrium
  • 42. Microscopic :  Formation of irregular , pink ,tan yellow cords or nodules of tumor  Involves endometrium and infiltrates myometrium as irregular tongues with LVI  Well differentiated endometrial stromal cells  Mild nuclear atypia  Necrosis rare
  • 43. IHC :  ER+ PR+ Androgen + WT-1 +  CD 10 ++  Smooth muscle actin +  Desmin less positive,30%  Negative – HDAC8 , H caldesmin  Nuclear Beta catenin + in 40% of cases
  • 44. Cytogenetics :  The most common translocation involves the short arm of chromosome 7 and the long arm of chromosome 17 [t(7;17)] leading to fusion of two zinc finger genes, JAZF1 and JJAZ1 (also referred to as SUZ12), and the production of the JAZF1/JJAZ1 gene fusion protein.  This is characteristic of ESS  Function of JAZF1, JJAZ1, or the JAZF1/JJAZ1 gene fusion has not been determined; however, in cultured cells, the fusion gene appears to modulate cell survival and proliferation  Other gene fusion proteins : t(6;7) JAZF1/PHF1 t(6;10) EPC1/PHF1
  • 45. Nature : LGESS  low grade  Favorable prognosis  Stage is prognostic STAGE 5Yr survival I, II 90% III, IV 50% Course :  Indolent  Late recurrences – early stage – 36-56% recurrences  Median time for recurrence – stage I-65months stage III,IV -9 months
  • 46. High Grade ESS :  Features between low grade ESS and undifferentiated  Age -28-67yrs  Presentation – abnormal vaginal bleeding enlarged uterus pelvic mass  Gross – intracavitatory polypoid and pelvic mass size upto 9cm  Shows extrauterine extension at time Of diagnosis
  • 47. Cut section :  Fleshy with extensive areas of necrosis and haemorrhage Microscopic:  High grade round cells with low grade spindle cell component – fibromyxoid  Mitotic activity - >10/10HPF  Necrosis +
  • 48. IHC :  C Kit + ER - PR - CD 10 - CYCLIN D1 ++
  • 49. Cytogenetics :  The t(10;17) rearrangement results in a 14-3-3 fusion to FAM22 (known as YWHAE-FAM22), leading to aberrant localization of 14-3-3 in the nucleus and possible oncogenic transformation  is associated with a high-grade variant of ESS  Clinically more aggressive and carries a worse prognosis  However, it does not display prominent nuclear pleomorphism, which is generally seen with UES
  • 50. Undifferentiated :  Heterogeneous group of sarcomas lacking diagnostic criteria for: ESS LMS Adenosarcoma with sarcomatous overgrowth Carcinosarcoma/poorly differentiated carcinoma  UES also expresses the receptor tyrosine kinase CD117 (c-KIT) and human epidermal growth factor receptor 2 (HER2 or ERBB2), which are not typically found in ESS.  Unlike ESS, there are no known chromosomal abnormalities associated with UES.
  • 51.  Rare  Post menopausal -60yrs  Presentation : post menopausal bleeding complaints secondary to extra-uterine disease  Usual presentation with Stage III,IV disease UES is always a diagnosis of exclusion
  • 52. Microscopic :  Myometrial invasion  Nuclear pleomorphism  High mitotic activity  Tumor cell necrosis lack smooth muscle or endometrial stromal differentiation  They lack the typical growth pattern and vascularity of low grade ESS and displace the myometrium in contrast to the infiltrative pattern of low grade ESS
  • 54.
  • 55. Imaging : • Ultrasound—non specific typically characterized as a heterogeneous hypoechoic endometrial mass, which can show extensive myometrial involvement
  • 56. larger size, more contrast enhancement, irregular margin, nodular extension into the myometrium, and marginal nodularity due to tumor extension along vessels and lymphatics
  • 58. Diagnosis BIOPSY POST HYSTERECTOMY • Baseline imaging • Confined to uterus– TAH+BSO • Extra uterine disease + Maximal Cytoreduction NO MORCELLATION NO Ovary Sparing • Baseline imaging • No second surgery for staging
  • 59. 2
  • 60. Role of Cytoreduction !!! • High-grade ESS, <2 cm of residual disease -- longer median OS – 52 versus 2 months • Low grade ESS – No clear role
  • 61.  older patients  black race  advanced stage  higher grade  lack of primary surgery,  nodal metastasis
  • 62. Adjuvant Therapy :  ESN – None  Low grade ESS – Stage I –observation Stage II-IV – hormonal therapy Radiotherapy can be given to reduce local recurrences  High grade ESS and Undiferrentiated ESS Adjuvant therapy to be given in all stages
  • 63. Low Grade ESS : no significant differences in the rate of recurrence between surveillance vs. adjuvant RT vs. progestin therapy STAGE 5yr OS 10yr OS I 84% 77% II 62% 49% III 58% - IV 37% - STAGE I
  • 64. Hormonal Therapy  Only in Low grade ESS Options :  Progestins--megestrol/medroxy progesterone  Aromatase inhibitors– Letrozole/Anastrazole  Gnrh Analogues Tamoxifen, as well as hormonal replacement therapy containing estrogens are contraindicated in patients after treatment of ESS
  • 65. Basis : Primary ESS ER α PR α PR β ERα ERβ PRα PRβ STEROIDS Proliferation and Differentiation of endometrial Stromal cells Normal endometrium Recurrent ESS ER α PR α PRβ Progestin's -- antiestrogenic activity after binding to progesterone receptor Medroxyprogesterone acetate (MPA)(250mg daily) Megestrole acetate (160mg daily) • Side effects : dramatic weight gain related to glucocorticoid activity, severe depression and thrombo- embolic complications
  • 66. • Aromatase inhibitors :-- reduce estrogen levels by inhibiting estrogen synthesis in peripheral sites and tumor tissues, which leads to reduced receptor-mediated growth stimulation 1st generation—aminoglutethemide 2nd generation—formestan,fadrozol 3rdgen. –nonsteroidal -- exesmestane(25mgday) letrozole(2.5mg/day) steroidal– anastrazole(1mg/day) • Gnrh Analogues :-they suppress ovarian estrogen production. additional growth inhibitory effect via intratumoral modulation of mitogenic signaling of growth factor receptors leuprolide, gosereline, triptorelin
  • 67.
  • 68. Drug of choice –Aromatase inhibitor
  • 69. Cytotoxic chemotherapy: ifosfamide , doxorubicin –most active  Hormonal options is exhausted  in the absence of hormonal receptors  when progression into a high-grade malignancy occurs Duration???
  • 70. Radiotherapy??? Radiotherapy helps to improve local control Can be given in stage II-IV ESS
  • 71. ESS :  Sampath et al.--showed a significant decrease in 5- year local–regional recurrence rate  Most studies--improvement in local control with adjuvant radiotherapy
  • 72. Undifferentiated ESS:  Poor OS regardless of stage  Due to high risk of recurrence regardless of stage , adjuvant chemotherapy should be given to all patients with UES.  Combination regimen eg: gemcitabine plus docetaxel is preferred STAGE MEDIAN PFS MEDIAN OS I 15months 27months II-IV 7months 12months
  • 73. Follow Up : NCCN • physical exam every three months for the first two years and then every 6 to 12 months. • CT scans of the chest, abdomen, and pelvis every 6 to 12 months (or as clinically indicated) for the first five years • Long term surveillance with CT scans shouldn't be done.
  • 74. Recurrent disease :  abdomen/pelvis (40 to 50 %)  lung ( 25 %)  Rare- spine  Treatment naïve --- hormone therapy • Recurrent disease post treatment • Metastatic disease Cytotoxic chemotherapy STAGE MEDIAN TIME I AND II 65 months III AND IV 9 months
  • 76. Mixed epithelial and mesenchymal tumours : Tumours of the uterine corpus composed of an epithelial and a mesenchymal component.  Carcinosarcoma **  Adenosarcoma  Carcinofibroma  Adenofibroma  Adenomyoma Atypical polypoid variant
  • 77. Carcinosarcoma(MMMT)  composed of an admixture of malignant epithelial and mesenchymal components.  <5 percent of all uterine malignancies  7th decade  Most common among sarcomas  Risk factors : obesity , diabetes , nulliparity,tamoxifen prior pelvic radiation  Presentation : vaginal bleeding >abdominal mass>pelvic pain  Examination : polypoid mass protruding through cervix and presents as upper vaginal mass
  • 78. There are 4 main theories regarding the histogenesis of CS: (1) the collision theory, (2) the combination theory, (3) the conversion theory (4) the composition theory . Now its clear that CS arises through conversion and metaplasia Dedifferentiated or Metaplastic endometrial carcinoma
  • 79. Imaging :  Ultrasound - hyperechoic compared with the myometrium. In addition, expansion of the endometrial canal is seen • CT scan —a heterogenous, ill defined, hypodense mass with concomitant dilatation of the endometrial canal..
  • 80. MRI :  enlarged uterus with a widened endometrial cavity and evidence of deep myometrial invasion.  Heterogenous bulky mass protruding into cervix  Prolonged intense enhancement CT
  • 81.  FDG PET/CT –useful for diagnostic and initial staging purposes. CS is generally positive on PET scan; the mean standardized uptake value (SUV) of 10+/-5.5  CA-125:  Preoperative CA125 elevation is a marker of extrauterine disease and deep myometrial invasion.  Postoperative CA125 elevation is an independent prognostic factor for poor survival
  • 82. Macroscopic : Polypoid , bulky, necrotic and hemorrhagic filling endometrium and invading myometrium Epithelial Mesenchymal Glandular Non glandular Homologous Heterologous endometroid squamous Undifferentiated Endometrial sarcoma Rhabdomyosarc oma serous undifferentiated Leiomyosarcoma chondrosarcoma Clear cell ESS liposarcoma Microscopic – Biphasic • Most common combination : high-grade serous carcinoma and an endometrial stromal sarcoma
  • 83. Uterine carcinosarcoma is a histologic diagnosis IHC : epithelial—anticytokeratin + mesenchymal –vimentin +
  • 85.
  • 86. Treatment :  Complete surgery -- total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node dissection, cytology of peritoneal washings, omentectomy, and biopsies of peritoneal surfaces • Lymphadenectomy is significantly associated with improved overall survival in patients with Stage I- III uterine carcinosarcoma • No survival benefit with radiotherapy
  • 87. Adjuvant therapy : Stage Ia :  No trials have evaluated the value of adjuvant chemotherapy specifically in women with stage IA disease  GOG 20– adjuvant doxorubicin vs surveillance. Low recurrence rates  GOG 55874- Adjuvant RT vs surveillance low local recurrence
  • 88. Stage IB-IV :  Adjuvant chemotherapy is preferred rather than RT or observation . Local relapse-- 44%-24%
  • 89.  whole abdominal- pelvic irradiation - 30.6 Gy to the whole abdomen and pelvis, f/b a 19.8 Gy pelvic boost or three cycles of cisplatin, ifosfamide and mesna (CIM)  No statistically significant difference was found in OS (45% CIM v 35% WAI) or DFS---58% WAI v 52% CIM  WAI led to a decline - vaginal failures (4% v 10%), no difference in pelvic failures (13%).  Estimated 5yr survival– 35% (WAI) vs 45% ( chemotherapy)  Adjuvant radiotherapy –more late complications Uncertain Role
  • 90. Chemotherapy regimen: Single Agent Chemotherapy :  Ifosfamide (36%) • etoposide (6.5%) • doxorubicin (9.8%) • cisplatin (18%) • paclitaxel (18%) • topotecan (10%) The regimen of chemotherapy recommended for use in early stage disease is the same as for late stage disease
  • 91. GOG trials for Carcinosarcoma: GOG 261, a Phase 3 randomized trial of ifosfamide and paclitaxel versus carboplatin and paclitaxel is ongoing…
  • 92. Role of radiotherapy!!! • Smith et al. & Nemani et al.—no survival benefit associated with adjuvant radiotherapy in stage I–III carcinosarcoma, • whereas Smith et al-- overall survival benefit -stage IV disease • Sampath et al.-decrease in local failure no change in overall survival
  • 93. EORTC : GCG 55874 study –CS • 224 patients –LMS(99), CS(92), and ESS(30). • External beam pelvic radiotherapy with observation in FIGO stage I and II disease . • With a median follow- up of 6.8 years, no difference was found in overall survival or disease-free survival . pelvic recurrences local recurrences Surgery alone 24% 47% Surgery + RT 4% 24%
  • 94. Rare Sarcomas :  Adenosarcoma  PEComa  Rhabdomyosarcoma
  • 95. Adenosarcoma :  Mixed tumor of low malignant potential  Benign glandular elements +low grade sarcoma  5-10% of all sarcomas  all ages, ranging from 15-90 years --median age at diagnosis of 58.  Risk factors :tamoxifen therapy for breast cancer prior pelvic radiation  Origin : endometrium in lower uterine segment rare-endocervix  Presentation :abnormal vaginal bleeding, an enlarged uterus and tissue protruding from the external os
  • 96. Gross : polypoid tumors of approximately 5–6 cm in maximum diameter (range, 1–20 cm) that typically fill and distend the uterine cavity Cut section – • tan brown with foci of haemorrhage and necrosis. • Small cysts • mostly do not invade myometrium
  • 97. Microscopic :  Periglandular cuffs—stroma concentrates around glands  Mild nuclear atypia  Few or no mitosis  Mesenchymal elements -10- 15% cases • Adenosarcoma With Sarcomatoid Overgrowth : Pure sarcomatous component >25% of total tumor volume • IHC : CD 10+ PR+ Ki 67+ cytokeratins
  • 99.  low grade  Recurs --25-40% of cases, typically in the pelvis or vagina, and distant metastasis 5%  Poor prognostic -- extrauterine spread, deep myometrial invasion sarcomatous overgrowth. Vascular invasion  Long- term follow-up is necessary because recurrences may manifest after many years. TREATMENT :  TAH+BSO  If sarcomatous overgrowth – adjuvant pelvic radiotherapy.
  • 100. PEComa(Perivascular epithelioid cell tumor):  Poorly defined, rare tumors characterized by varying amounts of epithelioid and spindle cells with clear to eosinophilic, granular cytoplasm that is HMB45+ in a diffuse or focal pattern  Mean age of 45 years (range, 9 - 79 years)  ~50 cases reported in English language literature  Sites-uterus and retroperitoneum  2 types – Benign & Malignant  Etiology unknown  Aggresive in nature and recurs post hysterectomy
  • 101. Gross:  polypoid mass  Solitary or rarely multifocal mass in uterine corpus from 0.6 to 12.0 cm (mean of 4.7 cm)  Cut sections may be grayish white, tan or yellow with whorled or soft, fleshy, ill defined or rarely circumscribed margins BENIGN: • tongue-like growth pattern similar to LGESS; • well defined cell borders, abundant granular or clear to eosinophilic cytoplasm, • Usually no / mild pleomorphism.no mitotic figures,no necrosis • Strong, diffuse cytoplasmic HMB45 expression and focal muscle marker expression Microscopic : BENIGN OR MALIGNANT
  • 102. Malignant :  diffuse sheets of cells, separately by occasional small, hyalinized bundles and plaques of stroma;  contain primarily perivascular epithelioid cells (> 50% are round or polygonal)  focal HMB45 expression, and  strong, extensive muscle marker expression  malignant features include mitotic activity > 1/10 HPF, necrosis, tumor size > 5 cm, infiltrative growth pattern, high nuclear grade, cytologic atypia, high cellularity, lymphovascular invasion, infiltration
  • 103. Positive Stains :  HMB45, SMA (73%), p53 (50%), melanA / MART1 (24% - 67%)  Also calponin, vimentin, h-caldesmon; PR (50%), desmin (49%), muscle specific actin (36%), ER (33%), CD10 (25%) Treatment : Hysterectomy, with or without adjuvant chemotherapy and radiotherapy
  • 104. Rhabdomyosarcoma :  Pure rhabdomyosarcoma arising in the uterus is a very rare tumor  mainly in elderly women,  highly malignant tumors with frequent extrauterine spread at presentation.  Patients rarely survive beyond 15 months.
  • 105.  uterine cervix and corpus are the most frequent locations of RMS in adult women.  Three categories: embryonal, alveolar, and pleomorphic  In postmenopausal women, uterine RMSs appear to be entirely the pleomorphic type with extremely poor clinical outcome.  The median progression-free survival (PFS) and disease- specific survival was 9 months and 21 months respectively.  The 5- year disease-specific survival was only 29%
  • 106. Radiotherapy practice:  No role of upfront Radiotherapy  It is given in adjuvant settings post surgery Indications :  High grade and undifferentiated endometrial sarcomas  Adenosarcomas, especially with sarcomatous overgrowth.  Carcinosarcomas early-stage comprehensively staged patients, intravaginal RT and chemotherapy stage III concurrent pelvic RT and cisplatin followed by carboplatin/paclitaxel.
  • 107.
  • 108. Technique :  CT based planning with CT taken with full bladder
  • 109. PTV final = ITV Vault + PTV total
  • 110. Dose to PTV final : 50Gy/25#/5wks  In case of carcinosarcoma We usually give Radiotherapy in a sandwich pattern with chemotherapy
  • 111. Chemotherapy in practice:  LMS  High grade ESS  Carcinosarcoma – Inj paclitaxel 175mg/m2 Inj carboplatin 5 AUC  Low grade ESS – Letrozole 2.5mg OD IAP 3 weekly for 6 cycles Inj ifosfamide 1.2gm/m2 Inj adriamycin 20mg/m2 Inj Cisplatin 50mg/m2
  • 113. • Retrospective review of medical records of patients of uterine sarcoma (20022007) • 42 (15 CS, 12 ESS, 11 LMS, 3 UES, and 1 mixed sarcoma • Adjuvant radiation, chemoradiation, and chemotherapy were offered. Pelvic radiation: 46 Gray/23 fractions/4.5 weeks and vincristine, adriamycin, cyclophosphamide (VAC) regimen were most commonly used • Median OS of only 6.57, 6.8, and 9.38 months, respectively, in patients with carcinosarcoma, leiomyosarcoma, and UES • Disease stage (p = 0.005) and response to therapy (p = 0.01)—predictors of OS • Small series, poor treatment compliance and socioeconomic constraints in the indian scenario were the limiting factors
  • 114. Conclusion :  Uterine sarcomas are very aggressive neoplasms  No imaging modality can offer a reliable preoperative diagnosis  As a result, centralisation, large series, and randomised trials are problematic.  Aggressive surgical cytoreduction at the time of initial diagnosis offers the best survival  To date, no effective adjuvant therapy has been found to prolong the survival of women with uterine sarcomas.  More RCTs are needed to determine the value and regime of adjuvant therapy